Several molecular mechanisms related to MET acquired resistance as well as genetic aberrations or phenotypic changes could contribute to cancer progression during treatment with EGFR-TKIs, leading to the loss of EGFR expression with the inability of TKIs to work efficiently. Here, EGFR is linked to cancer.